FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy. ➡️ Survie globale médiane : 9.0 mois ➡️ Survie sans progression médiane : 5.2 mois ➡️ Taux de réponse objective : 23.1% https://t.co/Yso8
98 followers
98 followers
RT @FrontOncology: New research: FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based c…
770 followers
RT @FrontOncology: New research: FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based c…
12,219 followers
RT @FrontOncology: New research: FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based c…